For instance, Mynott et al., 2021, demonstrated that the inhibition of P-gp using the specific inhibitor tariquidar glucosylceramide synthase did not enhance the efficacy of bortezomib or carfilzomib in MM cell lines, except at a high, clinically unachievable concentration [48]. This evidence concerns the gene PGP and Miyoshi myopathy.